RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- November 09, 2006 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that preclinical data on ADH-1 in combination with chemotherapy was presented today during a poster session at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” at the Prague Congress Centre, Prague, Czech Republic. The poster, entitled “Inhibition of N-cadherin enhances anti-tumor activity and overcomes chemoresistance in regional melanoma therapy,” was authored by C.K. Augustine1,3, Y. Yoshimoto1,3, P. Zipfel1,3, M.A. Selim2, and D.S. Tyler1,3, and will be made available on the Adherex website at www.adherex.com. The poster summarizes the unexpected and synergistic effects observed in the preclinical studies conducted at Duke using ADH-1 in combination with regional melanoma chemotherapy.
